Solid Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Solid Biosciences Inc 's ROA in the second quarter of 2026?
Solid Biosciences Inc recorded a cumulative net loss of $-207 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -52.87%.

However, within the Healthcare sector 621 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4048, from total ROA ranking in the first quarter of 2026 at 4698.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	107.25 %	23.33 %	23.66 %	29.75 %	33.87 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-207	-192	-174	-167	-154
Return On Assets (TTM)	-52.87 %	-62.03 %	-60.29 %	-60.11 %	-58.73 %
SLDB's Total Ranking	# 4048	# 4698	# 4126	# 4169	# 4236
Total Assets (TTM) in million	638	423	233	273	308
Seq. Total Assets Change	50.92 %	81.86 %	-14.89 %	-11.28 %	-10.19 %
Seq. Net Income Change	-	-	-	-	-

SLDB's 5 Years Annual ROA >> Back to SLDB Management Effectiveness >> Compare SLDB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 86
Sector	# 622
Overall	# 4008

Return On Assets Statistics
High	Average	Low
-7.44 %	-59.17 %	-143.22 %
(Mar 31 2018)		(Sep 30 2020)

News about Solid Biosciences Inc Return on Assets ROA

Solid Biosciences: Hope Amidst Financial Headwinds in Gene Therapy

Outlining the Facts:1. Underwritten Offering: - Solid Biosciences Inc. priced an underwritten offering of 35,739,810 shares at $4.03 per share and pre-funded warrants for 13,888,340 shares at $4.029 each. - The total gross proceeds from this offering are expected to be approximately $200 million. - The financing round is intended to support ongoing development in precision genetic medicines for neuromuscular and cardiac diseases. - The offering is expected to close on February 19, 2025, pending standard closing conditions.2. Financial Challenges: - The company reported a cumulative net loss of $102 million for the twelve months ending in Q3 2024. - Solid Biosciences has a negative return on assets (ROA) of -48.06%, indicating substantial operational inefficiencies. - In the healthcare sector, 573 companies outperformed Solid in terms of ROA, indicating the company is behind its peers financially.

Solid Biosciences: Balancing Financial Strain with Hope in Gene Therapy Innovation,

Solid Biosciences Inc. a trailblazer in the field of precision genetic therapies, has recently garnered attention with the FDA’s Fast Track designation for its dual-route gene therapy, SGT-212, aimed at treating Friedreich s ataxia (FA). This is a significant milestone as SGT-212 is the only dual-route gene transfer therapy under development that has received FDA Investigational New Drug (IND) clearance, positioning Solid as a unique player in this therapeutic landscape. However, the company is also grappling with significant financial challenges, as reflected in its latest financial disclosures. Financial PositionIn reporting a cumulative net loss of $102 million for the twelve months ending in the third quarter of 2024, Solid Biosciences finds itself amidst a difficult financial landscape. The company s return on assets (ROA) has plummeted to -48.06%, indicating an unsustainable operational model at this stage in their development. Comparatively, 569 other companies in the healthcare sector maintain a higher ROA, underscoring the competitive challenges Solid faces against more financially stable peers. Despite this, there is a silver lining in the company’s overall ROA ranking, which improved from 3811 to 3722 in the September 30, 2024 quarter. This shift hints at a potential turnaround, albeit gradual.

Financial Statements
Solid Biosciences Inc 's Assets	$ 638 million	SLDB's Balance sheet
Solid Biosciences Inc 's Income	$ -55 million	Quarterly SLDB's Income Statement
SLDB's Income by Division		See SLDB's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	23.66 %	14.41 %	-36.85 %	12.63 %	35 %
Total Assets in million	233	188	164	260	231
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-174	-125	-96	-86	-72
Annual Return On Assets	-74.97 %	-66.31 %	-58.42 %	-33.04 %	-31.24 %

SLDB's 5 Years Annual ROA >> Back to SLDB Management Effectiveness >> Compare SLDB ROA to its Competitors

More Return On Assets Ratios
SLDB's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SLDB's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SLDB's Competitors
Subscribers only: Roa for Solid Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for SLDB's Customers

You may also want to know
SLDB's Roi	SLDB's Inventory Turnover Ratio	SLDB's Growth Rates	SLDB's Dividend Comparisons
	SLDB's Profitability Ratios	SLDB's Asset Turnover Ratio	SLDB's Dividend Growth
SLDB's Roe	SLDB's Valuation Ratios	SLDB's Financial Strength Ratios	SLDB's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:25:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.